
Advances in **CANCER RESEARCH**

Volume 71

Edited by

George F. Vande Woude

*ABL—Basic Research Program
National Cancer Institute
Frederick Cancer Research and Development Center
Frederick, Maryland*

George Klein

*Microbiology and Tumor Biology Center
Karolinska Institutet
Stockholm, Sweden*



ACADEMIC PRESS

San Diego London Boston
New York Sydney Tokyo Toronto

Contributors to Volume 71 ix

FOUNDATIONS IN CANCER RESEARCH

p53 and ATM: Cell Cycle, Cell Death, and Cancer

Susan E. Morgan and Michael B. Kastan

- I. Introduction 1
- II. The p53 Tumor Suppressor Gene 2
- III. ATM 9
- IV. Cell Cycle Control 16
- References 19

Deletions of the Short Arm of Chromosome 3 in Solid Tumors and the Search for Suppressor Genes

Klaas Kok, Susan L. Naylor, and Charles H. C. M. Buys

- I. Tumor Suppressor Genes: The Concept 28
- II. Methods of Localizing Tumor Suppressor Genes 30
- III. Chromosome 3 Losses in Different Types of Tumors 35
- IV. Functional Assays of Tumor Suppression on Chromosome 3 54
- V. (Presumed) Tumor Suppressor Genes on the Short Arm of Chromosome 3 58
- VI. Evolutionary Aspects of Human Chromosome 3 73
- VII. Concluding Remarks 75
- References 77

Mutations Predisposing to Hereditary Nonpolyposis Colorectal Cancer

Päivi Peltomäki and Albert de la Chapelle

- I. Introduction 94
- II. The HNPCC Syndrome 95
- III. HNPCC and DNA MMR 97
- IV. Mutations Predisposing to HNPCC 101.
- V. Phenotypic Effects of MMR Gene Mutations 111

VI. Implications of Mutation Findings	114
References	115

Functional Aspects of Apoptosis in Hematopoiesis and Consequences of Failure

Sharon L. McKenna and Thomas G. Cotter

I. Introduction	122
II. Morphological and Biochemical Features of Apoptosis	123
III. Molecular Mechanisms in Apoptosis	125
IV. Functional Aspects of Apoptosis in the Hematopoietic System	131
V. Disruption of Apoptosis in Hematopoiesis	141
VI. Future Perspectives	152
References	154

Cyclin-Dependent Kinase Regulation during G1 Phase and Cell Cycle Regulation by TGF- β

Michael J. Ravitz and Charles E. Wenner

I. Introduction	166
II. Cyclins and Cyclin-Dependent Kinases	168
III. Conclusions	198
References	199

The Natural Somatic Mutation Frequency and Human Carcinogenesis

Andrew J. G. Simpson

I. Introduction	210
II. Somatic Mutation of Microsatellite Sequences	211
III. Somatic Mutations of Minisatellite Sequences	217
IV. Somatic Mutation of the <i>HPRT</i> Gene	217
V. The Frequency of Somatic Mutation in Solid Tissues Can Account for Multistep Carcinogenesis	221
VI. Cellular Proliferation as a Risk Factor for Cancer	222
VII. Germline Mutations	224
VIII. The Mutation Rate as the Fundamental Biological Pacemaker	231
IX. The Importance of Measuring Somatic Mutation Rates	233
X. The Mutational Clock and Cancer Prevention	234
References	235

CD44: Structure, Function, and Association with the Malignant Process

David Naor, Ronit Vogt Sionov, and Dvorah Ish-Shalom

I. Introduction	243
-----------------	-----

- II. CD44 Nomenclature 245
- III. CD44 Biochemical Structure 246
- IV. CD44 Expression on Normal Cells 253
- V. Hyaluronic Acid Is the Principal Ligand of CD44 259
- VI. Non-HA Ligands of CD44 272
- VII. Soluble CD44 274
- VIII. Genetic Control of CD44 Expression 275
- IX. CD44 Functions 275
- X. Involvement of CD44 in Physiological and Pathological Cell Activities 285
- XI. CD44 Association with the Malignant Process in Experimental Models 287
- XII. CD44 Expression in Human Neoplasms and Its Correlation with the Malignant Status 291
- XIII. CD44 Association with Malignancy: Some Practical Comments 304
- XIV. Conclusions 305
- References 307

Human Papillomaviruses and Cervical Cancer

Luisa Lina Villa

- I. Introduction 321
- II. Biology of Papillomaviruses 322
- III. Taxonomy and Genomic Variability of Papillomaviruses 325
- IV. Epidemiological Aspects 327
- V. HPV Interaction with Cofactors 330
- VI. Viral Persistence and Disease Progression 331
- VII. Viral Burden and Cervical Disease 333
- VIII. HPV in Cervical Screening Programs 333
- References 335

HER-2/neu Protein: A Target for Antigen-Specific Immunotherapy of Human Cancer

Mary L. Disis and Martin A. Cheever

- I. Introduction 344
- II. HER-2/neu Vaccines for Cancer Therapy 346
- III. Potential Pitfalls Associated with HER-2/neu-Specific Immunotherapy 356
- IV. HER-2/neu Specific Antibodies for Cancer Therapy 360
- V. Conclusion 366
- References 367